Long Term Osteoporosis Treatment with Denosumab in a Real-World Setting: Observations beyond 10 years

OBJECTIVES: Denosumab is often employed as a long-term therapy for treating patients with osteoporosis. Yet, scant data are available on the safety and efficacy of denosumab use beyond 10 years. Our objective was to retrospectively analyze our experience using denosumab for osteoporosis treatment in a real-world setting to provide efficacy and safety data, especially when used beyond a decade. METHODS: A retrospective analysis was performed of 4030 patients treated for osteoporosis with denosumab as part of routine rheumatology care. Patients with long-term use (n=750) were selected, as defined by ≥5 years cumulative exposure. This group was then stratified into those receiving ≥10-year cumulative exposure (n=400) and a reference group with exposure for 5-10 years (n=350), a duration established to be safe and effective from prior studies. Efficacy of denosumab was determined by analyzing sequential BMD. Safety was determined through chart review. Safety concerns of special interest, namely osteonecrosis of jaw and atypical femur fractures, were described in detail. RESULTS: 400 patients were identified with extended denosumab exposure ≥10 years. For these patients, BMD increased steadily with no evidence of plateau and surpassed the total hip surrogate thresholds associated with reduced fracture risk. Among safety concerns of special interest, we observed 18 cases of ONJ and 2 cases of AFF from the entire cohort, with no temporal relationship to duration of use. CONCLUSIONS: Based on our experience, we conclude that there is no evidence-based rationale for discontinuing denosumab after 10 years; rather, prolonged use appears to remain both safe and effective.

Authors

Institutions

Publication Details

Journal
The Journal of Clinical Endocrinology & Metabolism
Published
2026-11-20
DOI
https://doi.org/10.1210/clinem/dgag465
Primary Topic
Bone health and osteoporosis research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Long Term Osteoporosis Treatment with Denosumab in a Real-World Setting: Observations beyond 10 years

Barry L. Gruber, Conor N. Gruber, Ryan C Smith, Daniel M Borek
1 links
The Journal of Clinical Endocrinology & Metabolism
Bone health and osteoporosis research
article

Long Term Osteoporosis Treatment with Denosumab in a Real-World Setting: Observations beyond 10 years

Barry L. Gruber, Conor N. Gruber, Ryan C Smith, Daniel M Borek
article en

Abstract

OBJECTIVES: Denosumab is often employed as a long-term therapy for treating patients with osteoporosis. Yet, scant data are available on the safety and efficacy of denosumab use beyond 10 years. Our objective was to retrospectively analyze our experience using denosumab for osteoporosis treatment in a real-world setting to provide efficacy and safety data, especially when used beyond a decade. METHODS: A retrospective analysis was performed of 4030 patients treated for osteoporosis with denosumab as part of routine rheumatology care. Patients with long-term use (n=750) were selected, as defined by ≥5 years cumulative exposure. This group was then stratified into those receiving ≥10-year cumulative exposure (n=400) and a reference group with exposure for 5-10 years (n=350), a duration established to be safe and effective from prior studies. Efficacy of denosumab was determined by analyzing sequential BMD. Safety was determined through chart review. Safety concerns of special interest, namely osteonecrosis of jaw and atypical femur fractures, were described in detail. RESULTS: 400 patients were identified with extended denosumab exposure ≥10 years. For these patients, BMD increased steadily with no evidence of plateau and surpassed the total hip surrogate thresholds associated with reduced fracture risk. Among safety concerns of special interest, we observed 18 cases of ONJ and 2 cases of AFF from the entire cohort, with no temporal relationship to duration of use. CONCLUSIONS: Based on our experience, we conclude that there is no evidence-based rationale for discontinuing denosumab after 10 years; rather, prolonged use appears to remain both safe and effective.

The Journal of Clinical Endocrinology & Metabolism
Binghamton University (US), Children's Hospital of Philadelphia (US), Icahn School of Medicine at Mount Sinai (US)
Good health and well-being
Bone health and osteoporosis research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Long Term Osteoporosis Treatment with Denosumab in a Real-World Setting: Observations beyond 10 years — Barry L. Gruber, Conor N. Gruber, et al. · The Journal of Clinical Endocrinology & Metabolism (2026) | TGRS Research Map | TGRS